Mortality risk of long-term amiodarone therapy for atrial fibrillation patients without structural heart disease.

@article{Qin2015MortalityRO,
  title={Mortality risk of long-term amiodarone therapy for atrial fibrillation patients without structural heart disease.},
  author={Dingxin Qin and George Leef and Mian Bilal Alam and Rohit Rattan and Mohamad Bilal Munir and Divyang N. Patel and Furqan Khattak and Evan C Adelstein and Sandeep Jain and Samir F Saba},
  journal={Cardiology journal},
  year={2015},
  volume={22 6},
  pages={
          622-9
        }
}
BACKGROUND Amiodarone is often prescribed in the management of atrial fibrillation (AF) but is known to cause significant end-organ toxicities. In this study, we examined the impact of amiodarone on all-cause mortality in AF patients with structurally normal hearts. METHODS We performed a retrospective cohort analysis of all AF patients with structurally normal hearts who were prescribed antiarrhythmic drugs (AAD) for rhythm control of AF at our institution from 2006 to 2013 (n = 2,077… CONTINUE READING
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Amiodarone pulmonary toxicity.

VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.

  • Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2011
VIEW 2 EXCERPTS

Drug Substudy Investigators

AFFIRM First Antiarrhythmi
  • Maintenance of sinus rhythm in patients with atrial fibrillation. An AFFIRM Substudy of the First Antiarrhythmic Drug. J Am Coll Cardiol,
  • 2003
VIEW 1 EXCERPT